On Wednesday, Perrigo got a positive adjustment to its Relative Strength (RS) Rating, from 68 to 72.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an 80 or higher RS Rating as they launch their largest climbs. See if Perrigo can continue to show renewed price strength and hit that benchmark.
Perrigo is working on a consolidation with a 30.93 buy point. See if the stock can clear the breakout price in volume at least 40% above average.
Earnings growth rose last quarter from 8% to 107%, but revenue fell from -2% to -4%.
The company holds the No. 5 rank among its peers in the Medical-Generic Drugs industry group. Dr. Reddy's Labs ADR is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
